Profile data is unavailable for this security.
About the company
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
- Revenue in USD (TTM)1.53bn
- Net income in USD40.23m
- Incorporated1989
- Employees3.95k
- LocationIntegra Lifesciences Holdings Corp1100 Campus RoadPRINCETON 08540United StatesUSA
- Phone+1 (609) 275-0500
- Fax+1 (609) 750-4277
- Websitehttps://www.integralife.com/
Mergers & acquisitions
Acquired company | IART:NSQ since announced | Transaction value |
---|---|---|
Acclarent Inc | -22.95% | 280.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Warby Parker Inc | 697.80m | -55.06m | 1.96bn | 2.14k | -- | 6.21 | -- | 2.82 | -0.467 | -0.467 | 5.91 | 2.66 | 1.21 | 5.19 | 655.52 | 326,074.80 | -9.57 | -- | -11.95 | -- | 55.01 | 57.49 | -7.89 | -14.53 | 2.02 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
Novocure Ltd | 525.66m | -192.74m | 2.06bn | 1.45k | -- | 5.72 | -- | 3.91 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
Premier Inc | 1.34bn | 80.33m | 2.07bn | 2.80k | 30.81 | 1.08 | 10.53 | 1.55 | 0.6421 | 0.6421 | 11.34 | 18.35 | 0.3887 | 5.25 | 3.10 | 477,306.10 | 1.89 | 10.39 | 2.48 | 13.00 | 66.20 | 62.04 | 4.87 | 22.60 | 0.8226 | 143.62 | 0.276 | 19.11 | -6.76 | 2.44 | -34.17 | -15.30 | -2.29 | -- |
STAAR Surgical Co | 326.24m | 15.30m | 2.17bn | 1.06k | 142.99 | 5.53 | 104.99 | 6.66 | 0.3093 | 0.3093 | 6.62 | 8.00 | 0.7159 | 2.11 | 5.09 | 308,942.30 | 3.36 | 6.77 | 3.82 | 7.90 | 78.51 | 76.89 | 4.69 | 9.16 | 5.22 | -- | 0.0004 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
Conmed Corp | 1.26bn | 82.35m | 2.27bn | 4.00k | 28.07 | 2.65 | 14.69 | 1.80 | 2.62 | 2.62 | 40.12 | 27.76 | 0.545 | 1.73 | 5.55 | 315,387.00 | 3.56 | 0.8972 | 4.10 | 1.02 | 54.92 | 54.95 | 6.53 | 1.65 | 1.08 | 3.65 | 0.5369 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
Patterson Companies, Inc. | 6.57bn | 185.93m | 2.32bn | 7.60k | 13.19 | 2.36 | 8.46 | 0.3525 | 2.00 | 2.00 | 70.16 | 11.16 | 2.27 | 6.58 | 12.82 | 864,246.30 | 6.42 | 1.13 | 11.05 | 1.81 | 21.01 | 20.98 | 2.82 | 0.5157 | 0.7473 | 14.91 | 0.389 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
Quidelortho Corp | 2.86bn | -1.76bn | 2.33bn | 7.10k | -- | 0.7038 | -- | 0.8153 | -26.38 | -26.38 | 42.82 | 49.52 | 0.3696 | 2.67 | 8.92 | 403,197.20 | -22.79 | 11.34 | -25.57 | 12.91 | 48.13 | 62.71 | -61.65 | 20.93 | 0.807 | 0.8786 | 0.4207 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
10X Genomics Inc | 625.45m | -264.30m | 2.38bn | 1.26k | -- | 3.30 | -- | 3.80 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
Evolent Health Inc | 2.18bn | -141.23m | 2.42bn | 4.70k | -- | 2.28 | -- | 1.11 | -1.25 | -1.25 | 19.28 | 10.72 | 0.8316 | -- | 6.30 | 462,948.70 | -4.22 | -9.60 | -5.36 | -12.59 | 20.56 | 24.50 | -5.07 | -13.66 | -- | -0.0548 | 0.3272 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
UFP Technologies Inc | 407.33m | 47.88m | 2.43bn | 3.09k | 51.04 | 8.24 | 40.84 | 5.97 | 6.21 | 6.21 | 52.82 | 38.46 | 1.02 | 4.50 | 6.71 | 131,693.20 | 11.99 | 9.69 | 13.80 | 10.95 | 27.89 | 26.33 | 11.75 | 10.14 | 1.46 | 17.87 | 0.1039 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
Myriad Genetics, Inc. | 774.20m | -234.60m | 2.45bn | 2.70k | -- | 3.23 | -- | 3.17 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Integra Lifesciences Holdings Corp | 1.53bn | 40.23m | 2.49bn | 3.95k | 62.32 | 1.56 | 15.28 | 1.63 | 0.5079 | 0.5079 | 19.32 | 20.29 | 0.3912 | 1.56 | 6.06 | 387,632.80 | 1.03 | 3.33 | 1.11 | 3.68 | 61.48 | 63.67 | 2.63 | 7.99 | 3.35 | 6.66 | 0.5374 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
Enovis Corp | 1.82bn | -103.33m | 2.60bn | 6.55k | -- | 0.7855 | 19.16 | 1.43 | -1.89 | -1.50 | 33.29 | 60.33 | 0.3717 | 1.49 | 5.49 | 277,452.20 | -2.10 | -0.3569 | -2.32 | -0.41 | 58.12 | 48.19 | -5.66 | -1.06 | 1.03 | 0.9243 | 0.2879 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
LivaNova PLC | 1.19bn | -31.77m | 2.95bn | 2.90k | -- | 2.41 | 175.08 | 2.49 | -0.5911 | -0.5911 | 21.89 | 22.56 | 0.4985 | 2.57 | 6.11 | 408,634.10 | -1.33 | -6.01 | -1.54 | -7.42 | 67.89 | 66.99 | -2.67 | -13.56 | 2.71 | 2.52 | 0.3383 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
Tandem Diabetes Care Inc | 770.01m | -141.45m | 2.95bn | 2.40k | -- | 12.12 | -- | 3.83 | -2.17 | -2.17 | 11.82 | 3.76 | 0.8126 | 2.74 | 8.35 | 320,837.10 | -14.93 | -10.08 | -18.48 | -12.23 | 49.28 | 51.77 | -18.37 | -11.59 | 3.01 | -- | 0.5884 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
Envista Holdings Corp | 2.56bn | -120.40m | 2.95bn | 12.80k | -- | 0.7133 | 270.87 | 1.15 | -0.713 | -0.713 | 14.72 | 24.09 | 0.3904 | 3.89 | 6.29 | 200,226.60 | -1.83 | 1.94 | -2.15 | 2.34 | 56.35 | 57.65 | -4.70 | 5.29 | 1.93 | 5.09 | 0.2667 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.88m | 8.73% |
Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 5.92m | 7.51% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 5.90m | 7.49% |
AllianceBernstein LPas of 31 Mar 2024 | 3.22m | 4.09% |
Wellington Management Co. LLPas of 31 Mar 2024 | 3.21m | 4.07% |
Cooke & Bieler LPas of 31 Mar 2024 | 3.13m | 3.97% |
Boston Management & Researchas of 31 Mar 2024 | 2.96m | 3.75% |
Champlain Investment Partners LLCas of 31 Mar 2024 | 2.69m | 3.41% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.12m | 2.69% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.60m | 2.03% |